Skip to main content
OpenTrials
Completed

NCT Number: NCT02463435

Effect of Nutritional Intervention and Olive Oil in Severe Obesity

Obesity is a worldwide epidemic with increasing prevalence, specially severe obesity (Body Mass Index (BMI) ≥ 35 kg/m2). It is a multifactorial disease that involves genetic and environmental factors that lead to increased mortality from cardiovascular disease, diabetes, cancer, among others and impairs life quality. Most research on severe obesity focuses on surgical alternatives and their results, thus this clinical trial aims to evaluate the effect of a non-pharmacological approach based on nutritional intervention and supplementation with a functional food, the olive oil. It will analyze the effectiveness of interventions on: weight loss, improvements on body composition and inflammatory profile (TNF-alfa, interleucins 1, 6 and 10, adiponectin), insulin resistance and serum lipids control, changing eating habits and physical activity practice, modification on bone mineral density and sarcopenia, and reduction of cardiovascular risk and other diseases. Also, it will be investigated the influence of polymorphisms (Pro12Ala of PPAR-γ gene, -174G>C of IL6 gene e Trp64Arg of ADRB3 gene) on nutritional intervention effectiveness with and without olive oil. This research looks for improving severely obese patient's care and contributing to effective results by reducing costs and risk treatment. The investigators believe that this informations will contribute significantly to the scientific field, expanding the knowledge about severe obesity.

Completed

Looking for future studies?

Notify Me

Key information

About this study

After enrollment, patients undergo a diagnostic phase (baseline) with nutritional, anthropometric and body composition assessment (multifrequency bioelectrical impedance analysis and dual X-ray absorptiometry); investigation of clinical history; collecting blood samples; carotid artery intima-media thickness, heart rate variability and accelerometry assessments; and application of validated questionnaires to evaluate secondary outcomes. Patients will be randomized into three different treatment groups. Randomization will be stratified according to Body Mass Index (BMI) (BMI between 35 and 39,99 kg/m2 and BMI ≥ 40 kg/m2), allocation ratio 1:1:1 and parallel intervention. Then, trained nutritionists will deliver the intervention according to the patient group and they will be followed-up for 12 weeks, with visits each 4 weeks.

Interventions will be provided as follow:

Olive oil group: in order to evaluate the effect of only the extra virgin olive oil on primary and secondary outcomes, patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily (4 sachets per day, 2 at lunch and 2 at dinner).

Nutritional intervention group: patients assigned to this group will receive nutritional intervention consisting of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Resting Energy Expenditure (REE) will be calculated according to Horie-Waitzberg & Gonzalez equation developed for severe obese individual using current weight and lean body mass (Horie et al., 2011). Total energy expenditure (TEE) will be calculated multiplying REE by activity factor recommended by Institute of Medicine (Trumbo et al., 2005) and thermic effect of food (Hill, Wyat, Peters, 2012). Total energy value (TEV) of diet will be determined reducing 550 to 1100 kcal from TEE to reach 0.5 to 1.0 weekly weight reduction according to the patient's individual goal. Distribution of macronutrients will follow Dietary Reference Intake (DRI) recommendation: 45-65% of carbohydrates, 10-35% of proteins and 20-35% of lipids (Trumbo et al., 2002). Fat acids (FA) will be distributed as recommended by Sociedade Brasileira de Cardiologia (Sposito et al., 2007): ≤ 7% saturated FA, ≤ 20% monounsaturated FA and ≤ 7% polyunsaturated FA. Food plan prescription will distribute TEV in 4-6 meals. Motivation will be held to changing eating and lifestyle habits.

Nutritional intervention plus olive oil: this group will receive conventional intervention plus supplementation of 52 mL of extra virgin olive oil daily (4 sachets per day, 2 at lunch and 2 at dinner).

At the end of follow-up the same assessments performed at diagnostic phase will be held.

To detect a reduction of 10 kg, with standard deviation of 30, which is in agreement with the study of Rodrigues e Silveira (2011), with a two-sided 5% significance level and a power of 80%, a sample size of 50 patients per group will be necessary, given an anticipated dropout rate of 42,9%.

This research will be conducted at a capital of center Brazil, at Unidade de Pesquisa Clínica of Hospital das Clínica/UFG, Faculty of Medicine/UFG.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index ≥ 35 kg/m2
  • Residence in Goiânia or metropolitan area
  • Patients referred by Secretaria Municipal de Saúde to Severe Obese Nutrition Clinic

Exclusion criteria

  • To have already performed bariatric surgery
  • Pregnancy
  • Reduction greater than 8% of body weight in the past 3 months
  • To have been treated at Severe Obesity Nutrition Clinic or have received nutritional counseling in another place in the last 2 years
  • Anti-obesity drugs use
  • Regular utilization of anti-inflammatory drugs or corticosteroids
  • HIV/AIDS, heart failure, kidney failure, hepatic insufficiency, chronic obstructive pulmonary disease and cancer

Treatment and study plan

Nutritional Intervention

Behavioral

Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.

Nutritional intervention plus olive oil

Other

Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.

Olive Oil

Dietary Supplement

Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.

Primary outcomes

  1. Anthropometric measurements change

    Time frame: Baseline, week 12

    Measurements of weight, arm circumference and Body Mass Index (BMI) will be evaluated to assess anthropometric change.

  2. Body composition change

    Time frame: Baseline, week 12

    Body fat mass (BFM), body fat percentage (%BF) and body mass density (BMD) will be evaluated to assess body composition change. BFM and %BF will be assessed using multifrequency bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA) and BMD will be assessed using DXA.

Secondary outcomes

  1. Change in inflammation parameters

    Time frame: Baseline, week 12

    TNF-alfa

  2. Change in inflammation parameters

    Time frame: Baseline, week 12

    Interleucin 6 (IL6), IL1, IL10

  3. Change in inflammation parameters

    Time frame: Baseline, week 12

    Adiponectin

  4. Change in inflammation parameters

    Time frame: Baseline, week 12

    C-reactive protein (CRP)

  5. Change in inflammation parameters

    Time frame: Baseline, week 12

    Neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR)

  6. Change in metabolic parameters

    Time frame: Baseline, week 12

    Lipid profile (total cholesterol, LDL-c, HDL-c, VLDL-c), insulin resistance (HOMA-IR, glycated hemoglobin), fasting glycaemia, hemogram

  7. Change in kidney function

    Time frame: Baseline, week 12

    Creatinine, urea and uric acid

  8. Change in liver function

    Time frame: Baseline, week 12

    AST and ALT

  9. Change in thyroid function

    Time frame: Baseline, week 12

    TSH, T4 and parathyroid hormone

  10. Change in vitamins

    Time frame: Baseline, week 12

    Vitamin D, vitamin B12 and folic acid

  11. Change in minerals

    Time frame: Baseline, week 12

    Iron, calcium, sodium, potassium and zinc

  12. Change in cardiovascular risk using Global Risk Score (GRS)

    Time frame: Baseline, week 12

  13. Change in cardiovascular risk using Framingham Risk Score (FRS)

    Time frame: Baseline, week 12

  14. Change in cardiovascular risk using heart rate variability (HRV)

    Time frame: Baseline, week 12

  15. Change in cardiovascular risk using Homocystein level

    Time frame: Baseline, week 12

  16. Polymorphism Pro12Ala of Peroxisome Proliferator-Activated Receptor Alfa (PPAR-alfa)

    Time frame: Baseline, week12

    Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism

  17. PolymorphismTrp64Arg of Beta-3 Adrenergic Receptor (ADRB3) gene

    Time frame: Baseline, week12

    Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism

  18. Polymorphism -174G>C of Interleukin 6 (IL6) gene.

    Time frame: Baseline, week12

    Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism

  19. Change in physical activity practice using Global Physical Activity Questionnaire

    Time frame: Baseline, week 12

  20. Change in physical activity practice using accelerometry

    Time frame: Baseline, week 12

  21. Change in food intake using Food Frequency Questionnaire

    Time frame: Baseline, week 12

  22. Change in food intake using 24 hour recall

    Time frame: Baseline, week 12

  23. Change in bone health parameters

    Time frame: Baseline, week 12

    Change in the following variables: bone density using DXA, falls and fractures and sun exposure

  24. Change in obesity sarcopenia using muscle mass (evaluated using DXA)

    Time frame: Baseline, week 12

  25. Change in obesity sarcopenia using handgrip strength

    Time frame: Baseline, week 12

  26. Change in sarcopenia using usual gait speed

    Time frame: Baseline, week 12

  27. Adherence to nutritional intervention

    Time frame: Baseline, week 12

    It will be evaluated through changes in food consumption (food frequency questionnaire)

  28. Adherence to the health service

    Time frame: Baseline, week 12

    It will be evaluated through attendance to the clinic visits

  29. Change in symptoms of anxiety and depression using Hospital Anxiety and Depression Scale

    Time frame: Baseline, week 12

  30. Change in symptoms of binge eating disorderusing Binge Eating Disorder Scale

    Time frame: Baseline, week 12

  31. Change in musculoskeletal pain using Visual Analog Scale

    Time frame: Baseline, week 12

  32. Change in musculoskeletal pain using Nordic Musculoskeletal Questionnaire

    Time frame: Baseline, week 12

Sponsors and collaborators

Lead sponsor

Universidade Federal de Goias

Other

Collaborators

  • Grupo de Estudos em Obesidade Grave (GEOG)
  • Research Support Foundation of the State of Goiás
  • Unidade de Pesquisa Clinica (UPC) do Hospital das Clínicas/UFG

Registry information

Official study title

Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jun 4, 2015
Registry last updated
Nov 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.